Repositioning Candidate Details
| Candidate ID: | R0355 |
| Source ID: | DB00988 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Dopamine |
| Synonyms: | 2-(3,4-dihydroxyphenyl)ethylamine; 3-Hydroxytyramine; 3,4-Dihydroxyphenethylamine; 4-(2-aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-aminoethyl)catechol; 4-(2-aminoethyl)pyrocatechol; Oxytyramine |
| Molecular Formula: | C8H11NO2 |
| SMILES: | NCCC1=CC(O)=C(O)C=C1 |
| Structure: |
|
| DrugBank Description: | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. |
| CAS Number: | 51-61-6 |
| Molecular Weight: | 153.1784 |
| DrugBank Indication: | For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure |
| DrugBank Pharmacology: | Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. |
| DrugBank MoA: | Dopamine is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. In the brain, dopamine actas as an agonist to the five dopamine receptor subtypes (D!, D2, D3, D4, D5). |
| Targets: | Dopamine D2 receptor agonist; Dopamine D1 receptor agonist; Dopamine D5 receptor agonist; Dopamine D3 receptor agonist; Dopamine D4 receptor agonist; Sodium-dependent dopamine transporter inducer; Dopamine beta-hydroxylase ligand; 5-hydroxytryptamine receptor 1A binder; 5-hydroxytryptamine receptor 7 binder; D(1) dopamine receptor agonist; Sodium-dependent noradrenaline transporter inhibitor; Sodium-dependent serotonin transporter inhibitor; 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 3B; Superoxide dismutase [Cu-Zn]; Synaptic vesicular amine transporter |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |